Myomo Inc. (MYO) Options Positioning, Max Pain & Unusual Sweeps

MYO scores 33 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars: Fundamental Cash Engine scores 3/20 (ROIC -35%; FCF yield 0%), the weakest result in the set and the core driver of the low rating. Whale 13F Flow scores 9/20 (institutional accumulation and options positioning), Insider Conviction scores 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit scores 11/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet scores 5/20 (Altman Z 0.2; Piotroski F 4/9; Debt/Equity 0.5). For a prospective investor, the pattern is that the business is not currently converting revenue into cash, and the balance sheet forensic markers sit in weak territory. The rating frames the stock as a forensic-risk name, and the supporting metrics are consistent with that framing. This is an analytical read of the source data, not personalized advice.

Myomo Inc. (MYO) is a NYSE-listed issuer classified under the Health Care sector and the Industrial Specialties industry. Per the market data, the company reports a gross margin of 65.7%, indicating a high-margin product or service mix at the gross level. Specific product lines, customer segments, and revenue mechanics are — The profile section gives a market capitalization of $0.1B, which is consistent in scale with the $51.5M figure in market data.

Revenue rose from $19.2M to $32.6M to $40.9M across the three periods, while operating losses widened to -$14.4M in FY 2025 and FCF was -$16.3M. Per the market data, operating margin is -35.2%, net margin is -38.1%, and ROIC is -35%. The Forensic Balance Sheet metrics cited in the RQD rating are an Altman Z-Score of 0.2 and a Piotroski F-Score of 4/9, with Debt/Equity of 0.5. Cash fell from $24.4M to $14.1M between the FY 2024 and FY 2025 filings.

• 🐂 Primary Bull Case: Revenue grew from $19.2M to $40.9M across the three reported fiscal years while gross margin stood at 65.7%. With Fundamental Cash Engine at 3/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 7/20, sustained execution supports upside toward the top of the $0.61 – $1.88 52-week range.
• 🐻 Primary Bear Case: Operating income of -$14.4M, FCF of -$16.3M, ROIC of -35%, and an Altman Z-Score of 0.2 point to cash burn and forensic balance-sheet risk. Investors must weigh current valuation against -35.2% operating margins and a 1.00 macro beta if sector demand softens.

Upstream and downstream dependencies are — Sector correlations beyond the stated Health Care / Industrial Specialties classification are — The main second-order item a prospective investor should watch is the link between the reported cash decline (from $24.4M to $14.

• Key Question #1: What is the debt position, given that Debt is reported as N/A while Debt/Equity is cited as 0.5?
• Key Question #2: Which institutions hold MYO shares, and what is the direction of recent 13F changes?
• Key Question #3: What is the nature of the reported officer share sales relative to the company's compensation and vesting schedule?